HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: JOE-08-0166v1 200/2/199    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lemus, A. E Articles by Pérez-Palacios, G. Search for Related Content PubMed PubMed Citation Articles by Lemus, A. E Articles by Pérez-Palacios, G.

¹ Department of Reproductive Biology, Universidad Autónoma Metropolitana Iztapalapa, Mexico City P.C. 09340, Mexico² Department of Reproductive Biology, Instituto Nacional de Ciencias Médicas y Nutrición S. Zubirán, Mexico City P.C. 14000, Mexico³ National Institute of Perinatology and School of Medicine, Universidad Nacional Autónoma de México, Mexico City P.C. 11000, Mexico

(Correspondence should be addressed to A E Lemus; Email: anaelenalemus{at}prodigy.net.mx)

A number of clinical studies have demonstrated that norethisterone (NET), a potent synthetic progestin, restores postmenopausal bone loss, although its mode of action on bone cells is not fully understood, while the effect of naturally occurring progesterone in bone has remained controversial. A recent report claims that the potent effects of NET on osteoblastic cell proliferation and differentiation, mimicking the action of estrogens, are mediated by non-phenolic NET derivatives. To determine whether osteoblasts possess the enzymes required to bioconvert a progesterone receptor (PR) agonist into A-ring reduced metabolites with affinity to bind estrogen receptor (ER), we studied the in vitro metabolism of [³H]-labeled NET in cultured neonatal rat osteoblasts and the interaction of its metabolic conversion products with cytosolic –osteoblast ER, employing a competition analysis. Results indicated that NET was extensively bioconverted (36.4%) to 5-reduced metabolites, including 5-dihydro NET, 3,5-tetrahydro NET (3,5-NET) and 3β,5-tetrahydro NET (3β,5-NET), demonstrating the activities of 5-steroid reductase and two enzymes of the aldo-keto reductases family. Expression of Srd5a1 in neonatal osteoblast was well demonstrated, whereas Srd5a2 expression was not detected. The most striking finding was that 3β,5-NET and 3,5-NET were efficient competitors of [³H]-estradiol for osteoblast ER binding sites, exhibiting affinities similar to that of estradiol. The results support the concept that the interplay of 5-steroid reductase and aldo-keto reductases in osteoblastic cells, acting as an intracrine modulator system is capable to bioconvert a PR agonist into ER agonists, offering an explanation of the molecular mechanisms NET uses to enhance osteoblastic cell activities.